Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1937 1
1968 2
1969 1
1970 3
1972 1
1973 3
1974 1
1975 1
1976 1
1977 1
1978 4
1979 2
1980 3
1981 3
1982 1
1983 3
1984 2
1985 6
1986 5
1987 7
1988 8
1989 3
1990 6
1991 6
1992 3
1993 5
1994 4
1995 1
1996 5
1997 3
1998 1
1999 5
2000 3
2001 3
2003 3
2004 2
2005 7
2006 2
2007 2
2008 5
2009 5
2010 6
2011 5
2012 2
2013 5
2014 7
2015 5
2016 4
2017 5
2018 10
2019 2
2020 9
2021 7
2022 4
2023 6
2024 5
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

207 results

Results by year

Filters applied: . Clear all
Page 1
AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trial.
Mendell JR, Muntoni F, McDonald CM, Mercuri EM, Ciafaloni E, Komaki H, Leon-Astudillo C, Nascimento A, Proud C, Schara-Schmidt U, Veerapandiyan A, Zaidman CM, Guridi M, Murphy AP, Reid C, Wandel C, Asher DR, Darton E, Mason S, Potter RA, Singh T, Zhang W, Fontoura P, Elkins JS, Rodino-Klapac LR. Mendell JR, et al. Among authors: asher dr. Nat Med. 2025 Jan;31(1):332-341. doi: 10.1038/s41591-024-03304-z. Epub 2024 Oct 9. Nat Med. 2025. PMID: 39385046 Free PMC article. Clinical Trial.
Evaluation of rAAVrh74 gene therapy vector seroprevalence by measurement of total binding antibodies in patients with Duchenne muscular dystrophy.
Goedeker NL, Dharia SD, Griffin DA, Coy J, Truesdale T, Parikh R, Whitehouse K, Santra S, Asher DR, Zaidman CM. Goedeker NL, et al. Among authors: asher dr. Ther Adv Neurol Disord. 2023 Jan 24;16:17562864221149781. doi: 10.1177/17562864221149781. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 36710722 Free PMC article.
Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapy.
Potter RA, Moeller IH, Khan S, Haegel H, Hollenstein A, Steiner G, Wandel C, Murphy AP, Asher DR, Palatinsky E, Griffin DA, Mason S, Iannaccone ST, Zaidman CM, Rodino-Klapac LR. Potter RA, et al. Among authors: asher dr. Sci Rep. 2025 Jan 2;15(1):4. doi: 10.1038/s41598-024-84077-w. Sci Rep. 2025. PMID: 39747998 Free PMC article. Clinical Trial.
Familial spongiform encephalopathies.
Asher DM, Masters CL, Gajdusek DC, Gibbs CJ Jr. Asher DM, et al. Res Publ Assoc Res Nerv Ment Dis. 1983;60:273-91. Res Publ Assoc Res Nerv Ment Dis. 1983. PMID: 6218552 Review. No abstract available.
Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial.
Writing Committee for the REMAP-CAP Investigators; Estcourt LJ, Turgeon AF, McQuilten ZK, McVerry BJ, Al-Beidh F, Annane D, Arabi YM, Arnold DM, Beane A, Bégin P, van Bentum-Puijk W, Berry LR, Bhimani Z, Birchall JE, Bonten MJM, Bradbury CA, Brunkhorst FM, Buxton M, Callum JL, Chassé M, Cheng AC, Cove ME, Daly J, Derde L, Detry MA, De Jong M, Evans A, Fergusson DA, Fish M, Fitzgerald M, Foley C, Goossens H, Gordon AC, Gosbell IB, Green C, Haniffa R, Harvala H, Higgins AM, Hills TE, Hoad VC, Horvat C, Huang DT, Hudson CL, Ichihara N, Laing E, Lamikanra AA, Lamontagne F, Lawler PR, Linstrum K, Litton E, Lorenzi E, MacLennan S, Marshall J, McAuley DF, McDyer JF, McGlothlin A, McGuinness S, Miflin G, Montgomery S, Mouncey PR, Murthy S, Nichol A, Parke R, Parker JC, Priddee N, Purcell DFJ, Reyes LF, Richardson P, Robitaille N, Rowan KM, Rynne J, Saito H, Santos M, Saunders CT, Serpa Neto A, Seymour CW, Silversides JA, Tinmouth AA, Triulzi DJ, Turner AM, van de Veerdonk F, Walsh TS, Wood EM, Berry S, Lewis RJ, Menon DK, McArthur C, Zarychanski R, Angus DC, Webb SA, Roberts DJ, Shankar-Hari M. Writing Committee for the REMAP-CAP Investigators, et al. JAMA. 2021 Nov 2;326(17):1690-1702. doi: 10.1001/jama.2021.18178. JAMA. 2021. PMID: 34606578 Free PMC article. Clinical Trial.
Risk of Transmissibility From Neurodegenerative Disease-Associated Proteins: Experimental Knowns and Unknowns.
Asher DM, Belay E, Bigio E, Brandner S, Brubaker SA, Caughey B, Clark B, Damon I, Diamond M, Freund M, Hyman BT, Jucker M, Keene CD, Lieberman AP, Mackiewicz M, Montine TJ, Morgello S, Phelps C, Safar J, Schneider JA, Schonberger LB, Sigurdson C, Silverberg N, Trojanowski JQ, Frosch MP. Asher DM, et al. J Neuropathol Exp Neurol. 2020 Nov 1;79(11):1141-1146. doi: 10.1093/jnen/nlaa109. J Neuropathol Exp Neurol. 2020. PMID: 33000167 Free PMC article. Review.
207 results